Staff editor
Anna Chwalibóg, Chief Product Officer at Integral Solutions, talks about the opportunity to develop next-generation microbiome-based therapeutics for mental health and cognitive enhancement.
A new study asserts resB® Lung Support improves lung function through microbiome-mediated mechanisms along the gut-lung axis in asthmatic population
Industry
Sponsored by
A new study demonstrated that daily intake of Probi's proprietary strain Lacticaseibacillus paracasei 8700:2 significantly reduced cardiovascular disease risk.
Nathalie Corvaïa, Chief Scientific Officer at MaaT Pharma, gives an overview of preclinical and clinical results for MaaT013 and MaaT033.
Microbiomepost discussed with Herbert Tilg, Medizinische Universitat Innsbruck, Austria, about the importance of gut microbiome for intestinal and not intestinal health.
Osnat Tirosh, Head of Microbiome Research & Innovation at Biomica, talks about the validation of the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models.
Christophe Roca, Head of Pilot Department at Sacco System, talks about development and GMP production of Live Biotherapeutics for all applications.
Juan Basterra, CEO at Mikrobiomik, talks about the interim results on MBK-01, the first intestinal microbiota-based biological drug in phase 3 for both primary episode and recurrence of Clostridioides dificile.
With all aspects of LBPs covered in the summit, the 8th Microbiome Movement Summit in Boston became the hub for sharing the latest insights in LBP research and development.
Ongoing Phase 3 trial built on positive data from Phase 2 HERACLES study and ongoing early access program (EAP) in France: both datasets showed that MaaT013 was well-tolerated in immunocompromised…
